{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:43:43Z","timestamp":1782247423235,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973177"],"award-info":[{"award-number":["81973177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773562"],"award-info":[{"award-number":["81773562"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31900875"],"award-info":[{"award-number":["31900875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81703326"],"award-info":[{"award-number":["81703326"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019M662518"],"award-info":[{"award-number":["2019M662518"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018M630840"],"award-info":[{"award-number":["2018M630840"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019T120641"],"award-info":[{"award-number":["2019T120641"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018551","name":"Science and Technology Innovation Talents in Universities of Henan Province","doi-asserted-by":"publisher","award":["21HASTIT045"],"award-info":[{"award-number":["21HASTIT045"]}],"id":[{"id":"10.13039\/501100018551","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.apsb.2020.10.021","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T02:29:45Z","timestamp":1604111385000},"page":"750-762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors"],"prefix":"10.1016","volume":"11","author":[{"given":"Yihui","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1939-2863","authenticated-orcid":false,"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6381-611X","authenticated-orcid":false,"given":"Yahong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-643X","authenticated-orcid":false,"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2020.10.021_bib1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2006-07-028829","article-title":"PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase","volume":"109","author":"Chan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2020.10.021_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrc1837","article-title":"Protein-tyrosine phosphatases and cancer","volume":"6","author":"Ostman","year":"2006","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.apsb.2020.10.021_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.devcel.2006.01.002","article-title":"An Shp2\/SFK\/Ras\/Erk signaling pathway controls trophoblast stem cell survival","volume":"10","author":"Yang","year":"2006","journal-title":"Dev Cell"},{"key":"10.1016\/j.apsb.2020.10.021_bib4","doi-asserted-by":"crossref","first-page":"104595","DOI":"10.1016\/j.phrs.2019.104595","article-title":"Targeting SHP2 as a promising strategy for cancer immunotherapy","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2020.10.021_bib5","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1126\/sciadv.aay4458","article-title":"Molecular mechanism of SHP2 activation by PD-1 stimulation","volume":"6","author":"Marasco","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2020.10.021_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2020.10.021_bib7","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1038\/s41467-018-06814-w","article-title":"Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2","volume":"9","author":"P\u00e1dua","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.10.021_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0065-230X(10)06002-1","article-title":"The tyrosine phosphatase Shp2 in development and cancer","volume":"106","author":"Grossmann","year":"2010","journal-title":"Adv Canc Res"},{"key":"10.1016\/j.apsb.2020.10.021_bib9","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1158\/0008-5472.CAN-04-1923","article-title":"Activating mutations of the noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia","volume":"64","author":"Bentires-Alj","year":"2004","journal-title":"Canc Res"},{"key":"10.1016\/j.apsb.2020.10.021_bib10","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1021\/acs.jmedchem.7b01520","article-title":"Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment","volume":"60","author":"Xie","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.021_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/acschembio.7b00980","article-title":"Dual allosteric inhibition of SHP2 phosphatase","volume":"13","author":"Fodor","year":"2018","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.apsb.2020.10.021_bib12","doi-asserted-by":"crossref","first-page":"112657","DOI":"10.1016\/j.ejmech.2020.112657","article-title":"Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTACs degraders","volume":"204","author":"Tang","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.021_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.10.021_bib14","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/acs.jmedchem.8b01725","article-title":"Optimization of fused bicyclic allosteric SHP2 inhibitors","volume":"62","author":"Bagdanoff","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.021_bib15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/acs.jmedchem.8b00513","article-title":"Small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2","volume":"62","author":"Wu","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.021_bib16","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.tips.2017.03.004","article-title":"Targeting tyrosine phosphatases: time to end the stigma","volume":"38","author":"Stanford","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2020.10.021_bib17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.apsb.2011.10.007","article-title":"Mechanisms of acquired resistance to tyrosine kinase inhibitors","volume":"1","author":"Chen","year":"2011","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.10.021_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2020.10.021_bib19","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","article-title":"Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase","volume":"24","author":"Ruess","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.10.021_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.4497","article-title":"SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors","volume":"24","author":"Dardaei","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2020.10.021_bib21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2020.10.021_bib22","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1021\/acs.jmedchem.0c00471","article-title":"Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein","volume":"63","author":"Wang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2020.10.021_bib23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2020.10.021_bib24","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1021\/acs.biochem.5b01287","article-title":"Structural and functional consequences of three cancer-associated mutations of the oncogenic phosphatase SHP2","volume":"55","author":"LaRochelle","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2020.10.021_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd1063","article-title":"Designing screens: how to make your hits a hit","volume":"2","author":"Walters","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.10.021_bib26","series-title":"Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists","author":"Copeland","year":"2013"},{"key":"10.1016\/j.apsb.2020.10.021_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrd.2016.123","article-title":"Biophysics in drug discovery: impact, challenges and opportunities","volume":"15","author":"Renaud","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2020.10.021_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ab.2004.04.031","article-title":"Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery","volume":"332","author":"Lo","year":"2004","journal-title":"Anal Biochem"},{"key":"10.1016\/j.apsb.2020.10.021_bib29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.21769\/BioProtoc.1135","article-title":"Determination of pseudokinase-ligand interaction by a fluorescence-based thermal shift assay","volume":"4","author":"Lucet","year":"2014","journal-title":"Bio-protocol"},{"key":"10.1016\/j.apsb.2020.10.021_bib30","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"Niesen","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2020.10.021_bib31","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.3390\/molecules22122269","article-title":"Vanadium compounds as PTP inhibitors","volume":"22","author":"Irving","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2020.10.021_bib32","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2020.10.021_bib33","doi-asserted-by":"crossref","first-page":"13109","DOI":"10.1002\/chem.201903464","article-title":"Palladium-catalyzed \u2018on-water\u2019 tandem cyclization reactions for the synthesis of biologically important 4-arylquinazolines","volume":"25","author":"Yuan","year":"2019","journal-title":"Chem Eur J"},{"key":"10.1016\/j.apsb.2020.10.021_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s41061-020-0285-9","article-title":"Construction of biologically important biaryl scaffolds through direct C\u2013H bond activation: advances and prospects","volume":"378","author":"Yuan","year":"2020","journal-title":"Top Curr Chem"},{"key":"10.1016\/j.apsb.2020.10.021_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cclet.2019.07.019","article-title":"Br\u00f8nsted acid-promoted \u2018on-water\u2019 C(sp3)-H functionalization for the synthesis of isoindolinone\/[1,2,4]triazolo[1,5-a]pyrimidine derivatives targeting the SKP2\u2013CKS1 interaction","volume":"31","author":"Yuan","year":"2020","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2020.10.021_bib36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/adsc.201801226","article-title":"Br\u00f8nsted acid-catalyzed direct C(sp2)-H heteroarylation enabling the synthesis of structurally diverse biaryl derivatives","volume":"361","author":"Yuan","year":"2019","journal-title":"Adv Synth Catal"},{"key":"10.1016\/j.apsb.2020.10.021_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ab.2004.11.047","article-title":"6,8-Difluoro-4-methylumbiliferyl phosphate: a fluorogenic substrate for protein tyrosine phosphatases","volume":"338","author":"Welte","year":"2005","journal-title":"Anal Biochem"},{"key":"10.1016\/j.apsb.2020.10.021_bib38","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s10637-018-0626-5","article-title":"Inhibition of SHP2 by new compounds induces differential effects on RAS\/RAF\/ERK and PI3K\/AKT pathways in different cancer cell types","volume":"37","author":"Vazhappilly","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.apsb.2020.10.021_bib39","first-page":"10055","article-title":"Cytotoxic activity of Shp2 inhibitor fumosorinone in human cancer cells","volume":"15","author":"Chen","year":"2018","journal-title":"Oncol Lett"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520307723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383520307723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:48:08Z","timestamp":1761929288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383520307723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2211383520307723"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2020.10.021","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2020.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}